Enhanced Hydrophobic Auristatin F Compounds and Conjugates for Cancer Treatment

Improved hydrophobic Auristatin F compounds and conjugates with enhanced bystander activity, reduced immunogenicity, and improved efficacy against MDR+ cancer cells, providing a more effective treatment for cancer patients.

The original patent disclosed hydrophobic Auristatin F compounds and conjugates exhibiting activity against MDR+ cancer cells and bystander activity against cancer cells with lower copy number or undetectable levels of the targeted antigen. However, the original patent's limitations include the need for improved efficacy against MDR+ cancer cells, reduced immunogenicity, and enhanced bystander activity. The new inventive concept addresses these limitations by introducing novel linker moieties, hydrophobic modifications, and release mechanisms that enhance the conjugate's activity and reduce its immunogenicity.

The new inventive concept comprises a hydrophobic Auristatin F compound conjugate with a novel linker moiety that reduces immunogenicity and enhances bystander activity. The conjugate exhibits improved efficacy against MDR+ cancer cells due to the novel hydrophobic modification that enhances the retention of MDR+ activity. The conjugate is prepared using a novel method involving the synthesis of the linker moiety, conjugation to the hydrophobic Auristatin F compound, and purification of the resulting conjugate. The conjugate can be delivered using a system comprising a targeting moiety that selectively binds to the targeted antigen and a novel release mechanism that enhances the bystander activity of the conjugate.

The new claims introduce novel linker moieties, hydrophobic modifications, and release mechanisms that are not obvious from the original patent. The combination of these features provides a non-obvious solution to the limitations of the original patent, resulting in an inventive concept that is novel and non-obvious.

Alternative embodiments of the inventive concept include the use of different linker moieties, hydrophobic modifications, and release mechanisms. Additionally, the conjugate could be delivered using different targeting moieties or release mechanisms, or the method of preparation could be modified to include additional steps or different purification methods.

The enhanced hydrophobic Auristatin F compounds and conjugates have significant commercial potential in the treatment of cancer, particularly in the areas of MDR+ cancer cells and cancer cells with lower copy number or undetectable levels of the targeted antigen. The target market includes pharmaceutical companies, hospitals, and research institutions involved in cancer treatment and research.